Maxalt

Rizatriptan, the active ingredient in Maxalt, is a triptan presented as a tablet for oral use. It works by targeting serotonin 5‑HT1B/1D receptors to relieve migraine pain and is approved for the acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rizatriptan is a selective serotonin (5‑HT1B/1D) receptor agonist used in the acute management of migraine.

Migraine with aura: provides rapid relief of headache and associated neurological symptoms. Migraine without aura: reduces pain intensity and duration of the attack. Acute migraine attacks: improves functional ability and reduces the need for additional medication.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in the fingers or toes - Dizziness or light‑headedness - Nausea or abdominal pain - Fatigue or drowsiness

Serious or Rare Side Effects: - Serotonin syndrome, especially with other serotonergic agents - Coronary vasospasm or myocardial ischemia - Severe allergic reaction, including anaphylaxis - Persistent or worsening headache (rebound headache) - Hypertensive crisis in susceptible individuals

Before prescribing Rizatriptan, clinicians should consider several safety aspects.

Assess cardiovascular risk: avoid use in patients with uncontrolled coronary artery disease or recent myocardial infarction. Avoid concomitant ergot alkaloids: additive vasoconstriction may increase cardiovascular events. Do not exceed recommended dose: limit to one tablet per migraine attack and no more than ten tablets per month. Use caution in patients with hypertension: monitor blood pressure during treatment. Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Rizatriptan can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Ergot alkaloids: additive vasoconstriction may precipitate serious cardiovascular events. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may increase plasma concentrations of Rizatriptan. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise Rizatriptan exposure. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce Rizatriptan effectiveness.